KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBT: 2017-2024

Historic EBT for Adaptive Biotechnologies (ADPT) over the last 8 years, with Dec 2024 value amounting to -$159.6 million.

  • Adaptive Biotechnologies' EBT rose 129.74% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 59.25%. This contributed to the annual value of -$159.6 million for FY2024, which is 29.16% up from last year.
  • According to the latest figures from FY2024, Adaptive Biotechnologies' EBT is -$159.6 million, which was up 29.16% from -$225.3 million recorded in FY2023.
  • Adaptive Biotechnologies' 5-year EBT high stood at -$146.2 million for FY2020, and its period low was -$225.3 million during FY2023.
  • Its 3-year average for EBT is -$195.1 million, with a median of -$200.4 million in 2022.
  • Per our database at Business Quant, Adaptive Biotechnologies' EBT slumped by 113.14% in 2020 and then climbed by 29.16% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' EBT (Yearly) stood at -$146.2 million in 2020, then slumped by 41.76% to -$207.3 million in 2021, then increased by 3.34% to -$200.4 million in 2022, then declined by 12.45% to -$225.3 million in 2023, then climbed by 29.16% to -$159.6 million in 2024.